Previous studies have indicated that treatment of mice with anti-CD25 mAbs is only beneficial within a limited time window, in the later time points anti-CD25 mAbs will not only deplete Tregs, but also affect the effector cells that are involved in tumor rejection [24–26]. Here, IL2RA is linked to neoplasm.